Please use this identifier to cite or link to this item:
Title: Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Austin Authors: Parakh, S ;Murphy, C;Lau, D ;Cebon, Jonathan S ;Andrews, Miles C
Affiliation: Joint Austin-Ludwig Medical Oncology Unit, Austin Health, Heidelberg, Victoria, Australia
Ludwig Institute for Cancer Research - Austin Branch, Heidelberg, Victoria, Australia
Issue Date: 10-Nov-2014
Publication information: Journal of Clinical Pharmacy and Therapeutics 2014; 40(1): 121-3
Abstract: The management of metastatic melanoma has changed significantly in the past decade with the development of immunotherapies and targeted molecular therapies. Trials of targeted therapies have focused mainly on patients with the most common BRAF V600 mutations, namely V600E/K substitutions, with very little information available on the benefit of targeted therapies on less commonly occurring mutations such as V600R/D and M.We present a 54-year-old man with metastatic melanoma harbouring a rare BRAF V600M mutation, who experienced clinical and radiological response to combined therapy with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.As our understanding of these therapies evolves and an increasing number of patients have mutational testing performed, there is a clear imperative--as highlighted by this case--to test for rarer mutations and facilitate their inclusion both in everyday practice and in future clinical trials.
Gov't Doc #: 25382067
DOI: 10.1111/jcpt.12229
Type: Journal Article
Subjects: BRAF mutation
targeted therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.